- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears MammoScreen™ from Therapixel
Artificial intelligence tool designed to improve radiologist cancer detection performance.
Therapixel captured 510(k) clearance from the U.S. Food and Drug Administration this week for MammoScreen™, an explainable, actionable artificial intelligence (AI) tool designed to help with mammography interpretation.
The clearance comes after the release of findings from a multi-case study, company officials said, that showed radiologists had better cancer detection performance on mammograms when they used MammoScreen versus when they analyzed images solo.
“We believe MammoScreen will provide quick and reliable confirmation of radiologists’ suspicions as they read,” said Matthieu Leclerc-Chavlet, Therapixel chief executive officer. “This AI solution will ensure a more certain assessment by radiologists and a speedier reassurance of women having breast cancer screening exams, resulting in a more efficient workflow and reduced costs for the healthcare system.”
According to company information, MammoScreen can automatically detect and characterize suspicious soft tissue lesions and calcifications on mammography images while simultaneously assessing their likelihood of malignancy. Radiologists receive a summary report that categorizes each lesion’s suspiciousness on a scale of 1-to-10 with 10 being the most likely to indicate malignancy.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
